To put some numbers to trying to develop a single therapy (where candidates etc. will fail as you try them)
- Plan to sink $180-500M+ just in R&D
- Factor in failures, regulatory, clinical, recruitment, phase 1/2 trials and you arrive very quickly around $1.3-2.1 BILLION USD per therapy approved.
...there is a 90% chance that you will spend that $1B+ - and it will fail completely.
According to your numbers, Moderna got lucky at a 10% chance of producing the mRNA COVID-19 vaccine in 48 hours of computation? I don't know, but there seems to be more factors at play.
Moderna got lucky in that we know enough about that virus that the chance of a COVID-19 vaccine was a lot more than 10%. The more general case of a drug is a lot more than specific one
> Also, in 2018, just one year before the outbreak in a DARPA grant proposal, Wuhan Institute of Virology and its collaborators proposed to construct genetically modified SARS viruses having a furin cleavage site, a feature associated with increased viral growth and increased transmissibility. They proposed to insert the furin cleavage site at the spike gene S1/S2 border, and to construct the viruses by synthesizing six nucleic acid-building blocks, and assembling them using the reagent BsmB1.
> Fourth, in 2019, a novel SARS virus having a spike with extremely high binding affinity for human SARS receptors, a furin cleavage site inserted at the spike S1/S2 border, and a genome sequence with features enabling assembly from six synthetic nucleic acid building blocks using the reagent BsmB1--a virus having the exact features proposed into 2018 NIH and DARPA proposals--emerged on the doorstep of Wuhan Institute of Virology.
> Taken together, the presence of a spike having an extremely high affinity for human SARS receptors, the presence of a furin cleavage site inserted at the spike S1/S2 border, the genome sequence enabling assembly from six synthetic nucleic acid- building blocks using the reagent BsmB1, and the one-for-one match between these features and the features proposed in the 2018 NIH and DARPA proposals, make an extremely strong case--a smoking gun--for a research origin.
It raises questions that James Comer keeps raising to attack Fauci, but which never seem to get anywhere close to being proven. It's now been four years. The various libels against Fauci remain unsupported.
- Plan to sink $180-500M+ just in R&D
- Factor in failures, regulatory, clinical, recruitment, phase 1/2 trials and you arrive very quickly around $1.3-2.1 BILLION USD per therapy approved.
...there is a 90% chance that you will spend that $1B+ - and it will fail completely.
https://www.nature.com/articles/d41573-020-00043-x
https://greenfieldchemical.com/2023/08/10/the-staggering-cos...